Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy
Kalyan R. Chitturi, Ethan Burns, Ibrahim N. Muhsen, Kartik Anand, Barry Trachtenberg
Topics & Concepts
MedicineCardiotoxicityEpidermal growth factor receptorTrastuzumabTyrosine kinaseMonoclonal antibodyOncologyClinical trialInternal medicinePopulationEGFR inhibitorsTyrosine-kinase inhibitorPharmacologyToxicityImmunologyAntibodyCancerReceptorBreast cancerEnvironmental healthChemotherapy-induced cardiotoxicity and mitigationLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research